Clinical Cancer Epidemiology Group
Professor Amy Berrington’s group is investigating the late-effects of cancer treatments, medical radiation exposures and other medications to improve outcomes for patients.
Professor Amy Berrington
Group Leader:
Clinical Cancer Epidemiology
Professor Amy Berrington is an expert in the use of real world data to study the late-effects of cancer treatments, medical radiation exposures and other medications and is leading major studies in this field in breast and childhood cancer survivors. She is a member of multiple national and international advisory boards and is currently Vice-Chair of the US National Academy of Science Nuclear and Radiation Studies Board.
Researchers in this group
.
Recent discoveries from this group
Improved breast cancer risk tools on the horizon as major study reaches 20-year halfway point
Scientists are developing breast cancer risk tools that will help to identify women at high risk, even if they do not have a family history of the disease, thanks to one of the world’s largest and longest-running studies into the causes of breast cancer.
Largest study of its kind suggests physical activity reduces a woman’s risk of developing breast cancer before menopause
Regular leisure time physical activity may reduce the risk of breast cancer for women before menopause, according to new research funded by Breast Cancer Now.
New study reveals key priorities to guide US President Biden’s Cancer Moonshot
Researchers have revealed a set of recommendations to help reach the US Cancer Moonshot’s target of cutting cancer deaths by half in the next 25 years.